5
CCME Global
GENESISIBRCINDIALTD NSE
CCME Global
HealthcareNSE: GENESISIBRCINDIALTD BSE: 514336 Biotechnology
Key Fundamentals
MicrocapBiotechnologyHealthcareMarket Cap
₹136 Cr
Volatility
Low Risk
P/E Ratio
-150.4
EBITDA
₹0.20 Cr
Return on Equity
-0.35%
Debt to Equity
0
Book Value
₹8.86
52W High
₹184.9
52W Low
₹26.41
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
3- Stock is trading at 3.39 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.66% over last 3 years.
Growth Rate
Revenue Growth
-99%
Net Income Growth
-124%
Cash Flow Change
-55.79% lower than
3Y
ROE
—
ROCE
—
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 3.67 | 0 | 0 | 0 | 0 | 0 | 0.04 | 0 |
| Expenses | 0.06 | 0.02 | 0.02 | 3.69 | 0.1 | 0.02 | 0.03 | 0.02 | 0.12 | 0.06 | 0.03 | 0.54 | 0.24 |
| Operating Profit | -0.06 | -0.02 | -0.02 | -3.69 | -0.1 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 | -0.5 | -0.24 |
| OPM % | — | — | — | — | — | 99.46% | — | — | — | — | — | -1250% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 |
| PBT | -0.06 | -0.02 | -0.02 | -3.69 | -0.1 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 | -0.5 | -0.26 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.06 | -0.02 | -0.02 | -3.69 | -0.1 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 | -0.03 | -0.5 | -0.26 |
| EPS in Rs | -0.05 | -0.02 | -0.02 | -2.84 | -0.08 | 2.81 | -0.02 | -0.02 | -0.09 | -0.05 | -0.02 | -0.11 | -0.06 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.78 | 0 | 0 | 0.29 | 0.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04 |
| Expenses | 0.93 | 0.07 | 0.07 | 0.49 | 0.1 | 0.1 | 0.12 | 0.12 | 0.14 | 3.8 | 0.17 | 0.75 | 0.87 |
| Operating Profit | -0.15 | -0.07 | -0.07 | -0.2 | -0.05 | -0.1 | -0.12 | -0.12 | -0.14 | -3.8 | -0.17 | -0.75 | -0.83 |
| OPM % | -19.23% | — | — | -68.97% | -100% | — | — | — | — | — | 95.37% | -1775% | -2075% |
| Other Income | -0.09 | 0.42 | 0.07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.67 | 0.04 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 |
| PBT | -0.45 | 0.35 | 0 | -0.2 | -0.05 | -0.1 | -0.12 | -0.12 | -0.14 | -3.8 | 3.5 | -0.71 | -0.85 |
| Tax % | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -0.44 | 0.35 | 0 | -0.2 | -0.05 | -0.1 | -0.12 | -0.12 | -0.14 | -3.8 | 3.5 | -0.71 | -0.85 |
| EPS in Rs | -0.62 | 0.36 | 0 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | -0.16 | -0.24 |
| Div. Payout % | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.12 | 9.74 | 10 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 45.25 |
| Reserves | -3.7 | -3.35 | -3.35 | -3.55 | -3.7 | -3.8 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -5.18 |
| Borrowings | 0.17 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.3 | 5.24 |
| Total Liabilities | 4.52 | 7.1 | 6.68 | 9.52 | 9.38 | 9.32 | 9.2 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 4.66 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4.52 | 7.1 | 6.68 | 4.86 | 9.38 | 9.32 | 9.2 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
| Total Assets | 4.52 | 7.1 | 6.68 | 9.52 | 9.38 | 9.32 | 9.2 | 9.09 | 8.97 | 5.21 | 8.83 | 45.31 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -4.86 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0 | 0 | 5.1 |
| Investing | 0.77 | 0 | 0 | -4.66 | 4.66 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing | 4.1 | 2.62 | 0.26 | 3 | 0 | 0 | 0.12 | 0.12 | 0.09 | 0 | 0 | 32.25 |
| Net Cash Flow | 0.01 | -0.02 | 0.01 | 0.02 | -0.03 | 0.01 | 0 | 0 | -0.01 | 0 | 0 | 37.35 |
| Free Cash Flow | -4.09 | -2.64 | -0.25 | 1.68 | -4.69 | 0.01 | -0.12 | -0.12 | -0.09 | 0 | 0 | 5.1 |
| CFO/OP | 3,240 | 3,771 | 357 | -840 | 9,380 | -10 | 100 | 100 | 64 | 0 | 0 | -680 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 229 | — | — | 62.93 | 292 | — | — | — | — | — | — | — |
| Inventory Days | 0 | — | — | 0 | — | — | — | — | — | — | — | — |
| Cash Conversion Cycle | 229 | — | — | 62.93 | 292 | — | — | — | — | — | — | — |
| Working Capital Days | 1,586 | — | — | 5,991 | 67,890 | — | — | — | — | — | — | — |
| ROCE % | -16.62% | 6.88% | 0% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% | -2.92% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view CCME Global insights
56 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Intimation About Receipt Of Listing Approval For 32250000 Equity Shares Allotted On March 26, 2026
30 Apr - BSE approved listing of 3,22,50,000 equity shares issued at par on preferential basis. 30 Apr - BSE approved listing of 3,22,50,000 equity shares issued at par on preferential basis.
2
Intimation About Receipt Of Listing Approval For 32250000 Equity Shares Allotted On March 26, 2026
30 Apr - BSE approved listing of 3,22,50,000 equity shares issued at par on preferential basis. 30 Apr - BSE approved listing of 3,22,50,000 equity shares issued at par on preferential basis.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
17 Apr - Company confirms it is not a large corporate under SEBI circular as of 31 March 2026. 17 Apr - Company confirms it is not a large corporate under SEBI circular as of 31 March 2026.
4
Board Meeting Outcome for Outcome Of Board Meeting For Appointment Of Company Secretary, Compliance Officer And KMP. Also For Situation Of Corporate Office And Keeping Books Of Accounts At The Place Other Than Registered Office.
8 Apr - Board appointed Ms. Garima Garg as Company Secretary and Compliance Officer from April 8, 2026; books moved to Mumbai office. 8 Apr - Board appointed Ms. Garima Garg as Company Secretary and Compliance Officer from April 8, 2026; books moved to Mumbai office.
5
Announcement under Regulation 30 (LODR)-Change in Corporate Office Address
8 Apr - Ms. Garima Garg appointed Company Secretary and Compliance Officer effective April 8, 2026. 8 Apr - Ms. Garima Garg appointed Company Secretary and Compliance Officer effective April 8, 2026.
Frequently Asked Questions about CCME Global
What does CCME Global Ltd do?
CCME Global Ltd, formerly Genesis IBRC India Ltd and SSK Lifestyles Ltd, is transitioning from a non-operational biotechnology business towards FMCG, commodities, and minerals trading, manufacturing, and import-export activities under new management.[1]
Where is CCME Global Ltd (514336) listed?
CCME Global Ltd trades as GENESISIBRCINDIALTD on the NSE and under code 514336 on the BSE.
Which sector does CCME Global Ltd belong to?
CCME Global Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the market capitalisation of CCME Global Ltd?
CCME Global Ltd has a market capitalisation of ₹135.72 Cr, which places it in the Small Cap band.
What is the PE ratio of CCME Global Ltd?
CCME Global Ltd trades at a PE ratio of -150.40, against a book value of ₹8.86 per share.
What is the 52-week high and low of CCME Global Ltd?
Over the last 52 weeks CCME Global Ltd has traded between ₹26.41 and ₹184.9.
What is the Return on Equity (ROE) of CCME Global Ltd?
CCME Global Ltd reported a return on equity of -0.35%. Its debt-to-equity ratio is 0.00.
Company Information
CCME Global Ltd, formerly Genesis IBRC India Ltd and SSK Lifestyles Ltd, is transitioning from a non-operational biotechnology business towards FMCG, commodities, and minerals trading, manufacturing, and import-export activities under new management.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/514336.md for CCME Global Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.